Paul Tappenden BA (Nottingham Trent), MSc (Sheffield), PhD (Sheffield)
Professor of Health Economic Modelling
University of Sheffield
Regent Court, 30 Regent Street
Sheffield, S1 4DA
Tel: (+44) (0)114 222 0855
Fax: (+44) (0)114 222 0749
I have over 17 years’ experience in designing, developing and critically appraising health economic models across a wide range of disease areas. Since joining ScHARR in 2000, I have been involved in the assessment of numerous health technologies for the National Institute for Health and Care Excellence (NICE), including beta-interferon and glatiramer-acetate for multiple sclerosis, anti-TNFs for ulcerative colitis, inhaled therapies for cystic fibrosis and TKIs for medullary thyroid cancer. I have also undertaken modelling assessments for the National Institute for Health Research (NIHR) Evaluation, Trials and Studies Coordinating Centre (NETSCC), the Advisory Group for National Specialised Services (AGNSS), the Department of Health and NHS Cancer Screening Programmes, including an options appraisal of colorectal cancer screening programmes. In 2011, I completed an NIHR-funded fellowship evaluating the role and value of health economic models of whole disease and treatment pathways (Whole Disease Modelling).
I am the Director of Modelling for the ScHARR Technology Assessment Group and a member of the NICE Decision Support Unit (DSU). I am a member of NICE Technology Appraisal Committee C.
My main research interests are:
• Health economic modelling
• Conceptual modelling
• Whole disease modelling
• I am module lead for HAR691 (Using evidence in the design and development of models)
• I am an active PhD supervisor (3 current PhD students)
Amongst others, I am currently working on the following projects:
• Technology assessments to inform the NICE Technology Appraisal Programme (various)
• Economic analysis of interventions to improve adherence to nebulised therapies in patients with cystic fibrosis (alongside the CF ACtiF trial)
• Modelling the potential cost-effectiveness of interventions for amyotrophic lateral sclerosis (part of the ALS-CARE study)
- Tappenden P, Ren S, Archer R, Harvey R, Martyn-St James M, Basarir H, Stevens J, Lobo A & Hoque S (2016) A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. PharmacoEconomics, 34(10), 1023-1038. View this article in WRRO
- Tappenden P & Chilcott J (2014) Avoiding and Identifying Errors and Other Threats To the Credibility of Health Economic Models. Value in Health, 17(7), A585-A585.
- Tappenden P & Chilcott JB (2014) Avoiding and identifying errors and other threats to the credibility of health economic models.. Pharmacoeconomics, 32(10), 967-979.
- Tappenden P, Harnan S, Uttley L, Mildred M, Walshaw M, Taylor C & Brownlee K (2014) The Cost Effectiveness of Dry Powder Antibiotics for the Treatment of Pseudomonas aeruginosa in Patients with Cystic Fibrosis. PHARMACOECONOMICS, 32(2), 159-172.
- Tappenden P, Harnan S, Uttley L, Mildred M, Carroll C & Cantrell A (2013) Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.. Health Technol Assess, 17(56), v-181.
- Lord J, Willis S, Eatock J, Tappenden P, Trapero-Bertran M, Miners A, Crossan C, Westby M, Anagnostou A, Taylor S , Mavranezouli I et al (2013) Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.. Health Technol Assess, 17(58), v-192.
- Tappenden P, Chilcott J, Brennan A, Squires H, Glynne-Jones R & Tappenden J (2013) Using Whole Disease Modeling to Inform Resource Allocation Decisions: Economic Evaluation of a Clinical Guideline for Colorectal Cancer Using a Single Model. Value in Health.
- Tappenden P, Chilcott J, Brennan A, Squires H & Stevenson M (2012) Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework.. Value Health, 15(8), 1127-1136.
- Chilcott J, Tappenden P, Rawdin A, Johnson M, Kaltenthaler E, Paisley S, Papaioannou D & Shippam A (2010) Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.. Health Technol Assess, 14(25), iii-107.
- Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL, Kozak T, Farge-Bancel D, Madan J, Rafia R , Akehurst R et al (2010) Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.. Bone Marrow Transplant, 45(6), 1014-1021.
- Tappenden P, Chilcott J, Brennan A & Pilgrim H (2009) Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom.. Int J Technol Assess Health Care, 25(4), 470-478.
- Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R & Nicholson K (2009) Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.. Health Technol Assess, 13(11), iii-246.
- Tappenden P, McCabe C, Chilcott J, Simpson E, Nixon R, Madan J, Fisk JD & Brown M (2009) Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population.. Value Health, 12(5), 657-665.
- Tappenden P, Jones R, Paisley S & Carroll C (2007) The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.. Eur J Cancer, 43(17), 2487-2494.
- Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H & Karnon J (2007) Option appraisal of population-based colorectal cancer screening programmes in England.. Gut, 56(5), 677-684.